Therapy preference and decision-making among patients with severe sickle cell anemia and their families

Pediatric Blood and Cancer

Volumn 48, Issue 7, 2007, Pages 705-710

  Hankins, Jane ^a   Hinds, Pamela ^a   Day, Sara ^a   Carroll, Yvonne ^a   Li, Chin Shang ^a   Garvie, Patricia ^a   Wang, Winfred ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Decision making; Quality of life; Sickle cell anemia; Sickle cell disease

Indexed keywords

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DECISION MAKING; DISEASE SEVERITY; EMERGENCY WARD; FAMILY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MEDICAL INFORMATION; NURSE; PAIN; PARENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SICKLE CELL ANEMIA; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; DECISION MAKING; FEMALE; HUMANS; LIFE SUPPORT CARE; MALE; MIDDLE AGED; PARENTS; PATIENT CARE MANAGEMENT; PATIENT EDUCATION; PATIENT PARTICIPATION; PROFESSIONAL-FAMILY RELATIONS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248198838     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20903     Document Type: Article

References (25)

1. Cappellini MD, Cohen A, Piga A, et al. A phase 111 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 2006;107:3455-3462. Epub 2005 Dec. 13.
2. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-1587.
3. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-376.
4. Hankins J, Jeng M, Harris S, et al. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol 2005;27:158-161.
5. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-565.
6. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the stroke prevention trial (STOP) in sickle-cell anemia. J Pediatr 2001;139:785-789.
7. Quill TE, Brody H. Physician recommendations and patient autonomy: Finding a balance between physician power and patient choice. Ann Intern Med 1996;125:763-769.
8. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol 1997;34:42-47.
9. Kodish E, Lantos J, Stocking C, et al. Bone marrow transplantation for sickle cell disease. A study of parents' decisions. N Engl J Med 1991;325:1349-1353.
10. van Besien K, Koshy M, Anderson-Shaw L, et al. Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplant 2001;28:545-549.
11. Angst D, Deatrick J. Involvement in health care decisions: Parents and children with chronic ilness. J Fam Nurs 1996;2:174-194.
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
13. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-1554.
14. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-376.
15. Lynn MR. Determination and quantification of content validity. Nurs Res 1986;35:382-385.
16. Varni JW, Seid M, Rode CA. The PedsQL: Measurement model for the pediatric quality of life inventory. Med Care 1999;37:126-139.
17. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800-812.
18. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
19. Petitti D. Complex decision problems. Meta-analysis, decision analysis, and cost-effectiveness analysis methods for quantitative synthesis in medicine. New York: Oxford University Press. 2000; pp 140-158.
20. Eiser C, Vance YH, Horne B, et al. The value of the PedsQLTM in assessing quality of life in survivors of childhood cancer. Child Care Health Dev 2003;29:95-102.
21. Panepinto JA, O'Mahar KM, DeBaun MR, et al. Health-related quality of life in children with sickle cell disease: Child and parent perception. Br J Haematol 2005;130:437-444.
22. Sawyer M, Antoniou G, Toogood I, et al. A comparison of parent and adolescent reports describing the health-related quality of life of adolescents treated for cancer. Int J Cancer Suppl 1999;12:39-45.
23. Watson M, Wheatley K, Harrison GA, et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: Analysis of the MRC AML 10 trial. Cancer 1999;86:1231-1239.
24. Harrison MO, Edwards CL, Koenig HG, et al. Religiosity/spirituality and pain in patients with sickle cell disease. J Nerv Ment Dis 2005;193:250-257.
25. Deatrick JA, Woodring BC, Tollefson TL. Children should be seen and heard. Chronically ill children should have a voice in treatment decisions. Health Prog 1990;71:76-79.